Stock Report

All about this stock under one free report Last Updated: 21-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Avalo Therapeutics (AVTX) Key Ratios

Stock Card factsheet share-fund-plan-icon

$16.57

up-down-arrow $-0.12 (-0.72%)

As on 18-Sep-2026 16:08EDT

Market cap

info icon

$889 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

2

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- -86.62 -84.85 -60.88
EBIT -85.24 -75.14 -117.31 -240.63 -6.42
Net Profit -85.22 -75.09 -117.10 -227.05 -7.02
EPS 14.59 56.51 -7.54 25.80 14.85
Book Value -- -- -64.69 -- -65.14
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info -47,173.71-28,650.12-169,766.10-132,362.71-7,939.91
Net Margin info -----170,055.93----
Return on equity info 541.54117.13-37.74-72.43-50.06
Return on Capital info -165.00-165.93---71.44-49.67
Return on Assets info -71.85-85.01-30.98-58.58-40.91
Debt to Equity (x) info ----0.000.030.00

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
--
-71.44
-49.67
-373.88
-127.33
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-37.74

Higher than Peers by 2.69

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
-37.74
-72.43
-50.06
1,747.11
-684.77
Peer Median
-40.43
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-30.98

Higher than Peers by 0.48

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
-30.98
-58.58
-40.91
-116.06
-73.35
Peer Median
-31.46
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-169,766.10

Lower than Peers by 169,687.80

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
-169,766.10
-132,362.71
-7,939.91
-1,218.50
-207.52
Peer Median
-78.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-170,055.93

Lower than Peers by 169,967.01

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
-170,055.93
-132,642.37
-7,965.76
-1,639.50
-230.78
Peer Median
-88.92
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

-1.56

Lower than Peers by 1.56

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
-1.56
--
--
--
--
Peer Median
0.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

-86.62

Lower than Peers by 143.15

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
-86.62
-0.87
-0.77
-0.89
2.34
Peer Median
56.53
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-117.31

Lower than Peers by 116.67

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
-117.31
-123.03
-49.36
37.42
54.40
Peer Median
-0.64
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

-117.10

Lower than Peers by 110.02

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
-117.10
-122.78
-11.37
24.28
50.63
Peer Median
-7.08
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

-7.54

Lower than Peers by 22.20

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
-7.54
-0.26
0.91
0.96
0.50
Peer Median
14.65
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

6.56

Higher than Peers by 15.87

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
6.56
--
--
--
--
Peer Median
-9.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
--
0.03
0.00
0.07
-1.83
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.00

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
0.00
0.00
0.00
0.07
-0.59
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

19.31

Higher than Peers by 13.52

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
19.31
8.14
19.96
1.82
0.74
Peer Median
5.79
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

19.31

Higher than Peers by 13.65

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
19.31
--
--
1.82
0.74
Peer Median
5.66
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

--

--

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
--
--
-10.56
-6.86
-8.98
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

--

--

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
--
--
138.55
7.07
10.63
Peer Median
19.04
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.00

Lower than Peers by 0.06

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
0.00
0.00
0.01
0.07
0.32
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
--
3,782.50
309.34
195.06
67.97
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
--
--
--
2.84
3.08
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
--
222.97
-363.75
473.35
332.44
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
--
--
673.10
-275.44
-261.39
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
--
-4.30
-2.21
-0.23
0.00
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

1.99

Lower than Peers by 2.73

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
1.99
4.05
0.58
1.00
-0.02
Peer Median
4.72
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

-0.19

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
-0.19
-3.09
1.61
-0.02
-0.19
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

889

Higher than Peers by 746

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Avalo Therapeutics (AVTX)
889
--
--
--
--
Peer Median
143
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...